{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:12:30Z","timestamp":1770973950559,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004336","name":"Spanish Ministry","doi-asserted-by":"publisher","award":["CTQ2010-18195\/BQU"],"award-info":[{"award-number":["CTQ2010-18195\/BQU"]}],"id":[{"id":"10.13039\/501100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004336","name":"Spanish Ministry","doi-asserted-by":"publisher","award":["SAF2013-44844-R"],"award-info":[{"award-number":["SAF2013-44844-R"]}],"id":[{"id":"10.13039\/501100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004336","name":"Spanish Ministry","doi-asserted-by":"publisher","award":["AP2007-01665"],"award-info":[{"award-number":["AP2007-01665"]}],"id":[{"id":"10.13039\/501100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001370","name":"GVA","doi-asserted-by":"publisher","award":["ACOMP2013\/186"],"award-info":[{"award-number":["ACOMP2013\/186"]}],"id":[{"id":"10.13039\/100001370","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT)","award":["FCOMP-01-0124-FEDER-022718"],"award-info":[{"award-number":["FCOMP-01-0124-FEDER-022718"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.jconrel.2014.12.003","type":"journal-article","created":{"date-parts":[[2014,12,3]],"date-time":"2014-12-03T21:53:06Z","timestamp":1417643586000},"page":"80-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Polymer-doxycycline conjugates as fibril disrupters: An approach towards the treatment of a rare amyloidotic disease"],"prefix":"10.1016","volume":"198","author":[{"given":"Inmaculada","family":"Conejos-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Oteo-Vives","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Romero-Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amparo Ruiz","family":"Sauri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Morcillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Saraiva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7771-3373","authenticated-orcid":false,"given":"Mar\u00eda J.","family":"Vicent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2014.12.003_bb0005","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1021\/mp200394t","article-title":"Nanomedicine(s) under the microscope","volume":"8","author":"Gaspar","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0010","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jconrel.2014.05.001","article-title":"Polymer therapeutics: top 10 selling pharmaceuticals \u2014 what next?","author":"Duncan","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0015","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.copbio.2011.06.003","article-title":"Polymer-drug conjugates as nano-sized medicines","volume":"22","author":"Canal","year":"2011","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.addr.2012.08.012","article-title":"Polymer therapeutics-prospects for 21st century: the end of the beginning","volume":"65","author":"Duncan","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0025","series-title":"Drug Delivery Strategies: Polymer Therapeutics, Chapter 8.2","first-page":"456","author":"England","year":"2012"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0030","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2217\/nnm.10.71","article-title":"Polymer-drug conjugates for novel molecular targets","volume":"5","author":"Sanchis","year":"2010","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0035","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.addr.2009.05.006","article-title":"Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines","volume":"61","author":"Greco","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0040","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/polym6020515","article-title":"Peptide-based polymer therapeutics","volume":"6","author":"Duro-Castano","year":"2014","journal-title":"Polymers"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0045","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1039\/c3py00189j","article-title":"A versatile post-polymerization modification method for polyglutamic acid: synthesis of orthogonal reactive polyglutamates and their use in \u201cclick chemistry\u201d","volume":"4","author":"Barz","year":"2013","journal-title":"Polym. Chem."},{"issue":"2","key":"10.1016\/j.jconrel.2014.12.003_bb0050","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jconrel.2011.12.035","article-title":"Demonstrating the importance of polymer-conjugate conformation in solution on its therapeutic output: diethylstilbestrol (DES)-polyacetals as prostate cancer treatment","volume":"159","author":"Gimenez","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0055","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jconrel.2011.03.030","article-title":"Conformational consequences of cooperative binding of a coiled-coil peptide motif to poly(N-(2-hydroxypropyl) methacrylamide) HPMA copolymers","volume":"153","author":"Griffiths","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0060","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nmat1879","article-title":"Nanomedicine: industry-wise research","volume":"6","author":"Eaton","year":"2007","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0065","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jconrel.2012.06.016","article-title":"Improving the translation in Europe of nanomedicines (a.k.a. drug delivery) from academia to industry","volume":"164","author":"Eaton","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0070","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.addr.2009.06.003","article-title":"Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics","volume":"61","author":"Gaspar","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0075","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archneur.62.7.1057","article-title":"Transtyretin-related familial amyloidotic polyneuropathy","volume":"62","author":"Ando","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399402004647","article-title":"Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies","volume":"4","author":"Saraiva","year":"2002","journal-title":"Expert. Rev. Mol. Med."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0085","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1523\/JNEUROSCI.21-19-07576.2001","article-title":"Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways","volume":"21","author":"Sousa","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0090","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2174\/092986709787581888","article-title":"Soluble forms of RAGE in human diseases: clinical and therapeutical implications","volume":"16","author":"Santilli","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0095","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2014.01.019","article-title":"Targeting a rare amyloidotic disease through rationally designed polymer conjugates","volume":"178","author":"Conejos-S\u00e1nchez","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0100","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/brain\/122.10.1951","article-title":"Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features","volume":"122","author":"Misu","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0105","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/lv.2000.6145","article-title":"Liver transplantation for hereditary transthyretin amyloidosis","volume":"6","author":"Suhr","year":"2000","journal-title":"Liver Transpl."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0110","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jmb.2011.12.060","article-title":"The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug","volume":"421","author":"Johnson","year":"2012","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0115","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA tretment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0140","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1096\/fj.02-0764com","article-title":"4\u2032-Iodo-4\u2032-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters","volume":"17","author":"Cardoso","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0145","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1096\/fj.05-4509com","article-title":"Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model","volume":"20","author":"Cardoso","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0150","doi-asserted-by":"crossref","first-page":"41647","DOI":"10.1074\/jbc.M111.274548","article-title":"Testing the therapeutic potential of doxycycline in a Drosophila melanogaster model of Alzheimer disease","volume":"286","author":"Costa","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2217\/14796708.4.2.167","article-title":"Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases","volume":"4","author":"Lue","year":"2009","journal-title":"Future Neurol."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07388550601166458","article-title":"Microbial biosynthesis of polyglutamic acid biopolymer and applications in the biopharmaceutical, biomedical and food industries","volume":"27","author":"Buescher","year":"2007","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0165","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1517\/13543784.2011.576666","article-title":"Paclitaxel poliglumex for ovarian cancer","volume":"20","author":"Galic","year":"2011","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0170","doi-asserted-by":"crossref","first-page":"13159","DOI":"10.1016\/S0040-4020(99)00809-1","article-title":"4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride: an efficient condensing agent leading to the formation of amides and esters","volume":"55","author":"Kunishima","year":"1999","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0175","doi-asserted-by":"crossref","first-page":"16912","DOI":"10.1021\/ja054260y","article-title":"N-Triazinylammonium tetrafluoroborates. a new generation of efficient coupling reagents useful for peptide synthesis","volume":"127","author":"Kami\u0144ski","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0180","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/S0002-9440(10)64469-0","article-title":"Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro","volume":"161","author":"Sousa","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0185","doi-asserted-by":"crossref","first-page":"584","DOI":"10.2119\/2007-00068.Macedo","article-title":"Biomarkers in the assessment of therapies in familial amyloidotic polyneuropathy","volume":"13","author":"Macedo","year":"2007","journal-title":"Mol. Med."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0190","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0195","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0168-3659(01)00309-1","article-title":"Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANC","volume":"74","author":"Maeda","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0200","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.aca.2008.09.066","article-title":"A reversed-phase high performance liquid chromatography coupled with resonance Rayleigh scattering detection for the determination of four tetracycline antibiotics","volume":"630","author":"Wang","year":"2008","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0205","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrd1088","article-title":"The dawning era of polymer therapeutics","volume":"2","author":"Duncan","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0210","series-title":"Bioconjugate Techniques","author":"Hermanson","year":"2010"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tibtech.2005.11.006","article-title":"Polymer conjugates: nanosized medicines for treating cancer","volume":"24","author":"Vicent","year":"2006","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0220","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.addr.2009.08.001","article-title":"Polymer therapeutics: clinical applications and challenges for development","volume":"61","author":"Vicent","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0225","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.copbio.2011.05.507","article-title":"Polymer therapeutics as nanomedicines: new perspectives","volume":"22","author":"Duncan","year":"2011","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0230","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1021\/bm1003338","article-title":"Drug mimic induced conformational changes in polymer-drug conjugates characterized by small angle neutron scattering","volume":"11","author":"Paul","year":"2010","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0235","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0002-9440(10)65065-1","article-title":"4\u2032-Iodo-4\u2032-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid","volume":"156","author":"Palha","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0240","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0014-5793(00)02380-2","article-title":"Anti-amyloidogenic activity of tetracyclines: studies in vitro","volume":"487","author":"Forloni","year":"2001","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0250","series-title":"Unfolded Proteins: From Denatured to Intrinsically Disordered","author":"Creamer","year":"2008"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0255","series-title":"Part B: Molecular Mechanisms of Conformational Diseases","article-title":"Protein misfolding, aggregation and conformational diseases","author":"Uversky","year":"2007"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0260","unstructured":"C. Li, S. Wallace, D.F. Yu, D. Yang, Water soluble paclitaxel derivatives, Patent, Application number US9906870, (1999)."},{"key":"10.1016\/j.jconrel.2014.12.003_bb0265","series-title":"Nanotechnology for Cancer Therapy","author":"Amiji","year":"2006"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0270","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2147\/nano.2006.1.4.375","article-title":"Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate","volume":"1","author":"Chipman","year":"2006","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0275","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jconrel.2005.09.033","article-title":"Paclitaxel poliglumex (XYOTAX\u2122, CT-2103), a macromolecular taxane","volume":"109","author":"Singer","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.12.003_bb0280","first-page":"2116","article-title":"Comparison of distribution of doxycycline in mice after oral and intravenous application measured by a high-performance liquid chromatographic method","volume":"31","author":"Bocker","year":"1981","journal-title":"Arzneimittelforschung"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365914007834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365914007834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T23:51:48Z","timestamp":1566085908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365914007834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":53,"alternative-id":["S0168365914007834"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.12.003","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymer-doxycycline conjugates as fibril disrupters: An approach towards the treatment of a rare amyloidotic disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}